Buy Like Buffett
Watchlist

Flagship explainer

What drives 4D Molecular Therapeutics, Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−28%Tax burden100%net income ÷ pretax incomeInterest burden88%pretax ÷ operating incomeOperating margin−187%operating income ÷ revenueAsset turnover0.15×revenue ÷ average assetsEquity multiplier1.11×average assets ÷ average equityAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$140MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
Income before tax−$140MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
Operating income−$160MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
$85.2MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
Ending assets$567MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
Beginning assets$560MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
$506MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
$511MFY2024
  • 10-K · FY 2024Filing detailsAccession 0001193125-26-114075 · filed Mar 18, 2026
Source: · event Dec 31, 2025 · retrieved Nov 10, 2026 · annual-row source set
Embed this chart

View the full 4D Molecular Therapeutics, Inc. analysis at Buy Like Buffett